Aceruloplasminemia
- PMID: 25168455
- DOI: 10.1111/neup.12149
Aceruloplasminemia
Abstract
Aceruloplasminemia is characterized by progressive neurodegeneration with brain iron accumulation due to the complete lack of ceruloplasmin ferroxidase activity caused by mutations in the ceruloplasmin gene. Redox-active iron accumulation was found to be more prominent in the astrocytes than in the neurons. The most characteristic findings were abnormal or deformed astrocytes and globular structures of astrocytes. The lack of ceruloplasmin may primarily damage astrocytes in the aceruloplasminemic brains as a result of lipid peroxidation due to massive iron deposition. In the normal brain, iron may be continuously recycled between astrocytes and neurons, with transferrin acting as a shuttle. The glycosylphosphatidylinositol (GPI)-linked ceruloplasmin on astrocytes functions as a ferroxidase, mediating the oxidation of ferrous iron transported from the cytosol by ferroportin and its subsequent transfer to transferrin. In cases with aceruloplasminemia, neurons take up the iron from alternative sources of non-transferrin-bound iron, because astrocytes without GPI-linked ceruloplasmin cannot transport iron to transferrin. The excess iron in astrocytes could result in oxidative damage to these cells, and the neuronal cell protection offered by astrocytes would thus be disrupted. Neuronal cell loss may result from iron starvation in the early stage and from iron-mediated oxidation in the late stage. Ceruloplasmin may therefore play an essential role in neuronal survival in the central nervous system.
Keywords: ceruloplasmin; ferroportin; ferroxidase; hepcidin; iron; iron metabolic cycle; neurodegeneration.
© 2014 Japanese Society of Neuropathology.
Similar articles
-
Aceruloplasminemia, an iron metabolic disorder.Neuropathology. 2003 Dec;23(4):345-50. doi: 10.1046/j.1440-1789.2003.00521.x. Neuropathology. 2003. PMID: 14719552
-
Aceruloplasminemia: an update.Int Rev Neurobiol. 2013;110:125-51. doi: 10.1016/B978-0-12-410502-7.00007-7. Int Rev Neurobiol. 2013. PMID: 24209437 Review.
-
Aceruloplasminemia.Curr Drug Targets. 2012 Aug;13(9):1190-9. doi: 10.2174/138945012802002320. Curr Drug Targets. 2012. PMID: 22515740 Review.
-
[Neuronal cell damage in aceruloplasminemia].Nihon Shinkei Seishin Yakurigaku Zasshi. 2000 Oct;20(4):161-7. Nihon Shinkei Seishin Yakurigaku Zasshi. 2000. PMID: 11215401 Review. Japanese.
-
Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia.EMBO Mol Med. 2018 Jan;10(1):91-106. doi: 10.15252/emmm.201708361. EMBO Mol Med. 2018. PMID: 29183916 Free PMC article.
Cited by
-
Hemochromatosis-How Not to Overlook and Properly Manage "Iron People"-A Review.J Clin Med. 2024 Jun 23;13(13):3660. doi: 10.3390/jcm13133660. J Clin Med. 2024. PMID: 38999226 Free PMC article. Review.
-
Research progress on ferroptosis in gliomas (Review).Oncol Lett. 2023 Nov 27;27(1):36. doi: 10.3892/ol.2023.14169. eCollection 2024 Jan. Oncol Lett. 2023. PMID: 38108075 Free PMC article. Review.
-
A New Pathogenic Missense Variant in a Consanguineous North-African Family Responsible for a Highly Variable Aceruloplasminemia Phenotype: A Case-Report.Front Neurosci. 2022 May 2;16:906360. doi: 10.3389/fnins.2022.906360. eCollection 2022. Front Neurosci. 2022. PMID: 35585918 Free PMC article.
-
A Turkish Patient with Aceruloplasminemia Found to Have a Novel Pathogenic Variant Presenting with High Ferritin Level and Microcytic Anemia.Turk J Haematol. 2023 Dec 5;40(4):288-290. doi: 10.4274/tjh.galenos.2023.2023.0270. Epub 2023 Sep 12. Turk J Haematol. 2023. PMID: 37698253 Free PMC article. No abstract available.
-
Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.Orphanet J Rare Dis. 2020 Apr 25;15(1):105. doi: 10.1186/s13023-020-01385-w. Orphanet J Rare Dis. 2020. PMID: 32334607 Free PMC article.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical